CPIX

Strategic Transaction with Apotex Health

• Over 99% of voting shareholders approved the transaction, which closed on July 1, 2026. Apotex acquired all of Cumberland's FDA-approved commercial brands and related U.S. commercial organization.
• Cumberland received $100 million in cash at closing, with an additional $11 million scheduled for inventory and transition payments, plus a potential $10 million milestone payment. A special $1.50 per share dividend totaling $22 million was declared and funded after closing.
• The transaction transforms Cumberland from a commercial specialty pharmaceutical company to an innovation-focused biopharmaceutical company exclusively focused on advancing its clinical pipeline.

Clinical Pipeline Progress

• Duchenne Muscular Dystrophy (DMD) Program: Efetroban, developed to preserve cardiac function in DMD-associated cardiomyopathy, has received FDA Fast Track, Orphan Drug, and Rare Pediatric Disease designations. New positive biomarker data was presented at the 2026 Parent Project Muscular Dystrophy Annual Conference. Discussions with the FDA regarding the regulatory pathway are ongoing, with a follow-up meeting scheduled for fall 2026.
• Systemic Sclerosis (SSc) Program: Patient enrollment for the Phase 2 efetroban study is complete, and data evaluation is underway, with top-line results expected in 2026.
• Idiopathic Pulmonary Fibrosis (IPF) Program: An independent safety review of the first patient cohort found no new safety signals, so enrollment has continued. Interim efficacy results are expected in 2026.
• Oncology Collaboration with Vanderbilt Health: Positive Phase 2 results were announced in Q2 2026 for efetroban in preventing cancer metastasis in high-risk solid tumor patients. The therapy met the primary safety endpoint, and generated encouraging efficacy signals including lower metastatic recurrence and metastasis-related death rates compared to placebo. Next steps for the program are being evaluated.

Cumberland Emerging Technologies (CET)

• CET remains a key strategic asset that identifies, supports, and advances early biomedical innovations from leading academic research institutions. It complements internal development efforts by expanding pipeline access and creating future growth opportunities.

Financial Position Post-Transaction

• After the special dividend and transaction-related taxes (estimated at less than $1 million), Cumberland expects to retain net proceeds of approximately $108 million. Remaining cash is projected to fund all operations for more than five years, with over $50 million in additional reserves for strategic opportunities or unexpected expenses. The company fully retired its $5.2 million bank line of credit at the end of Q2 2026, strengthening its balance sheet.

• Management reaffirmed that following the Apotex transaction, the company is positioned with sufficient capital to fund all clinical development operations for more than five years, while holding over $50 million in additional reserves for unplanned strategic opportunities or expenses.
• Multiple key clinical milestones are expected to be completed and announced in the remainder of 2026: top-line results from the Phase 2 systemic sclerosis program, interim efficacy results from the Phase 2 idiopathic pulmonary fibrosis program, and further updates on regulatory planning for the DMD program.

Cumberland Pharmaceuticals completed the divestiture of its branded U.S. commercial business segment to Apotex Health on July 1, 2026. For Q2 2026, revenue and expenses from the former commercial segment are classified as discontinued operations. The only ongoing operating segment is clinical development of new product candidates, which generated an operating loss of $3.1 million in Q2 2026. Including discontinued operations, the company reported a net loss of $4.1 million for the quarter. As of June 30, 2026, the company held total assets of $63 million (including $4 million in cash and cash equivalents), with total liabilities of $46 million and total shareholders' equity of approximately $17 million.

• Forward-looking statements regarding clinical development progress, regulatory outcomes, future financial performance, and strategic opportunities are qualified by known risk factors, including the impact of natural disasters, economic downturns, international conflicts, trade restrictions, and public health epidemics, all of which are outside of the company's control and could cause actual results to differ materially from expectations.
• Clinical development of novel therapies carries inherent risk: there is no guarantee that any efetroban program will receive FDA approval, even after positive early and mid-stage data.
• All forward-looking statements are current only as of the date of the earnings call, and the company does not undertake any obligation to update statements to reflect future new information or developments.

No investor questions were submitted during the open Q&A portion of the call. Management noted that shareholders interested in private follow-up discussions could contact the company to schedule individual conversations.